» Articles » PMID: 25131091

Clinical Porcine Islet Xenotransplantation Under Comprehensive Regulation

Overview
Journal Transplant Proc
Specialty General Surgery
Date 2014 Aug 19
PMID 25131091
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Xenotransplantation with porcine islets is a promising approach to overcome the shortage of human donors. This is the first report of phase 1/2a xenotransplantation study of encapsulated neonatal porcine islets under the current framework of regulations for xenotransplantation in New Zealand.

Methods: Newborn piglets were anesthetized and bled, and the pancreata were removed with the use of sterile technique and processed. Encapsulated neonatal porcine islets were implanted with the use of laparoscopy into the peritoneal cavity of 14 patients with unstable type 1 diabetes without any immunosuppressive drugs. The patients received encapsulated islets of 5,000 (n = 4; group 1), 10,000 (n = 4; group 2), 15,000 (n = 4; group 3), or 20,000 (n = 2; group 4) islet equivalents per kg body weight. Outcome was determined from adverse event reports, HbA1c, total daily insulin dose, and frequency of unaware hypoglycemic events. To assess graft function, transplant estimated function (TEF) scores were calculated. Sufficient or marginal numbers of encapsulated neonatal porcine islets were transplanted into streptozotocin-induced diabetic B6 mice as an in vivo functional assay.

Results: There were 4 serious adverse events, of which 3 were considered to be possibly related to the procedure. Tests for porcine endogenous retrovirus DNA and RNA were all negative. The numbers of unaware hypoglycemia events were reduced after transplantation in all groups. Four of 14 patients attained HbA1c <7% compared with 1 at baseline. The average TEF scores were 0.17, 0.02, -0.01, and 0.08 in groups 1, 2, 3, and 4 respectively. The in vivo study demonstrated that a sufficient number of the transplanted group reversed diabetes with positive porcine C-peptide.

Conclusions: Transplantation of encapsulated neonatal porcine islets was safe and was followed by a reduction in unaware hypoglycemia events in unstable type 1 diabetic patients. The mouse in vivo assessment data demonstrated certain graft function.

Citing Articles

Status of islet transplantation and innovations to sustainable outcomes: novel sites, cell sources, and drug delivery strategies.

Wong J, Pepper A Front Transplant. 2024; 3:1485444.

PMID: 39553396 PMC: 11565603. DOI: 10.3389/frtra.2024.1485444.


Pig Xenotransplantation in Beta Cell Replacement: Addressing Challenges and Harnessing Potential for Type 1 Diabetes Therapy.

Piemonti L, Citro A, Tomajer V, Partelli S, Caldara R Transpl Int. 2024; 37:13122.

PMID: 39512630 PMC: 11540633. DOI: 10.3389/ti.2024.13122.


Cutting edge of immune response and immunosuppressants in allogeneic and xenogeneic islet transplantation.

Yue L, Li J, Yao M, Song S, Zhang X, Wang Y Front Immunol. 2024; 15:1455691.

PMID: 39346923 PMC: 11427288. DOI: 10.3389/fimmu.2024.1455691.


Impact of oxygen and glucose availability on the viability and connectivity of islet cells: A computational study of reconstructed avascular human islets.

Felix-Martinez G, Osorio-Londono D, Godinez-Fernandez J PLoS Comput Biol. 2024; 20(8):e1012357.

PMID: 39137218 PMC: 11343470. DOI: 10.1371/journal.pcbi.1012357.


Establishment of a donor pig for xenotransplantation clinical trials based on the principle of Changsha Communiqué.

Ma X, Li S, Wang J, Xu C, Wang W Health Care Sci. 2024; 2(2):129-134.

PMID: 38938766 PMC: 11080849. DOI: 10.1002/hcs2.37.